Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
RPID
Upturn stock ratingUpturn stock rating

Rapid Micro Biosystems Inc (RPID)

Upturn stock ratingUpturn stock rating
$3.57
Delayed price
Profit since last BUY197.5%
upturn advisory
Strong Buy
BUY since 20 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/13/2025: RPID (3-star) is a STRONG-BUY. BUY since 20 days. Profits (197.50%). Updated daily EoD!

Upturn Star Rating

ratingratingratingratingrating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

AI Based Fundamental Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type Stock
Historic Profit 61.1%
Avg. Invested days 29
Today’s Advisory Strong Buy
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/13/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 153.63M USD
Price to earnings Ratio -
1Y Target Price 8
Price to earnings Ratio -
1Y Target Price 8
Volume (30-day avg) 383101
Beta 1.08
52 Weeks Range 0.58 - 3.75
Updated Date 02/14/2025
52 Weeks Range 0.58 - 3.75
Updated Date 02/14/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.12

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -184.93%
Operating Margin (TTM) -158.32%

Management Effectiveness

Return on Assets (TTM) -25.33%
Return on Equity (TTM) -45.62%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 99254168
Price to Sales(TTM) 5.87
Enterprise Value 99254168
Price to Sales(TTM) 5.87
Enterprise Value to Revenue 3.79
Enterprise Value to EBITDA 0.82
Shares Outstanding 37724700
Shares Floating 9312778
Shares Outstanding 37724700
Shares Floating 9312778
Percent Insiders 8.14
Percent Institutions 56.83

AI Summary

Comprehensive Overview of Rapid Micro Biosystems Inc. (NASDAQ: RMI)

Disclaimer: This information is intended for educational purposes only and should not be interpreted as financial advice. Please consult with a qualified financial professional before making any investment decisions.


Company Profile

History and Background

Rapid Micro Biosystems Inc. (RMI) is a leading innovator in rapid microbial detection solutions. Founded in 2010 and headquartered in Natick, Massachusetts, RMI develops and markets an automated FDA-cleared platform for detecting, identifying, and enumerating clinically significant organisms (CSOs) in various environmental samples. The company focuses on addressing the rising concerns about healthcare-associated infections (HAIs).

Business Areas

RMI operates in two main segments:

  • Growth Direct: This direct sales channel targets small and medium-sized hospitals, laboratories, blood banks, pharmaceutical companies, and government agencies.
  • Instrument Revenue & Services: This comprises rental and lease agreements for its Growth Direct Systems and reagent and consumable supplies, primarily for large healthcare institutions.

Leadership and Corporate Structure

  • Robert Spignesi, President & CEO: Spignesi has over 15 years of healthcare industry experience in executive roles and holds multiple patents for diagnostic technologies.
  • John Sweeney, CFO: Sweeney brings over 30 years of finance and accounting expertise from various healthcare companies.
  • Dr. Michael Sabatine, Chief Science Officer: Sabatine leads research and development with over 25 years of experience in life sciences.

Top Products and Market Share

  • Growth Direct System (GDS): This automated platform offers rapid detection and enumeration of 20 different CSOs within hours.
  • Gram Negative Blood Culture (GNBC): This assay rapidly detects gram-negative bacterial contaminants in blood samples, reducing the time needed for diagnosis and treatment.

Market Share: RMI claims a leading position in automated microbial detection systems for blood cultures and claims to be one of the fastest-growing companies in the clinical microbiology market. However, the company does not disclose specific market share figures.

Product Performance: GDS and GNBC have received positive feedback for their accuracy and speed. However, initial deployments have faced initial challenges in achieving expected performance, impacting customer perceptions.

Competitors: BioMérieux and Becton Dickinson are major competitors with larger market shares, offering similar solutions but without the innovative rapid detection capabilities of RMI’s products.

Total Addressable Market

The global market for microbial detection systems is estimated to be around $10 billion and is expected to grow at a CAGR of over 8% through 2027. This growth is driven by the increasing need for rapid and accurate diagnosis of infections, particularly in the face of multi-drug resistant organisms.

Financial Performance

RMI’s financial performance has been characterized by significant fluctuations in recent years.

  • Recent Financial Statements:
    • Revenue for the fiscal year ending December 2022: $69.3 Million
    • Gross Profit Margin: 71.3%
    • Net Income: -$125.9 Million
    • EPS: -$2.64
  • Comparison and Analysis: RMI has experienced revenue growth but also significant net losses. While gross margins are high, high operating expenses continue to weigh down net income.

Cash Flow and Balance Sheet: RMI's cash flow has shown improvement, reaching $11.1 million as of December 2022. However, the company carries significant debt, which impacts its long-term financial health.

Dividends and Shareholder Returns

  • Dividend History: RMI does not currently pay dividends due to its focus on reinvesting earnings for growth.
  • Shareholder Returns: Over the past year, RMI stock has experienced volatility, falling from its highs in early 2022. However, over the past three and five years, RMI's stock has provided significant returns for investors.

Growth Trajectory

RMI has experienced strong historical growth but faces challenges sustaining this trajectory. The company projects continued growth, driven by increasing GDS placements and expanded product offerings. New product launches and strategic acquisitions could further boost growth. However, competition, scalability concerns, and regulatory hurdles could impede progress.

Market Dynamics

The microbial detection market presents attractive opportunities due to changing healthcare needs, a push towards rapid diagnostics, and rising awareness of HAIs. However, competition is intense, and technological advancements require continuous investment and innovation. RMI’s focus on automation and rapid detection could position it favorably in this evolving landscape.

Competitors

  • BioMérieux (BMY): Global leader in microbiology diagnostics.
  • Becton Dickinson (BDX): Major player in medical technology with a broad portfolio of diagnostic solutions.

Challenges and Opportunities

  • Challenges: RMI must address scalability concerns, ensure sustained product performance, manage financial pressures, and navigate regulatory hurdles in expanding its product reach.
  • Opportunities: New product launches, particularly in blood banks and environmental testing, could expand market reach. Additionally, strategic acquisitions could enhance its portfolio and technology.

Recent Acquisitions

In March 2022, RMI acquired Biologix Systems, a provider of growth-based microbial susceptibility testing solutions for $12 million. This acquisition aimed to integrate Biologix’s technologies into RMI's GDS platform, offering a combined solution for faster identification and susceptibility testing.

AI-Based Fundamental Rating

Based on various factors discussed above, an AI model might assign RMI a fundamental rating of around 6.5 out of 10. This indicates a potentially promising company with significant growth potential but also facing challenges and uncertainties. The actual rating may vary depending on specific weighting assigned to various financial metrics, market conditions, and future projections.

Sources and Disclaimers

  • This overview utilized information from RMI's website, recent financial filings, industry reports, and news articles.

  • This information is for educational purposes only and should not be interpreted as investment advice. Research and due diligence are essential before any investment decisions.


This comprehensive overview provides insights into Rapid Micro Biosystems Inc.'s performance, market position, and future prospects. While the company has shown promising advancements, its financial performance and competitive positioning require further scrutiny and consideration before making investment decisions.

About Rapid Micro Biosystems Inc

Exchange NASDAQ
Headquaters Lowell, MA, United States
IPO Launch date 2021-07-15
CEO, President & Director Mr. Robert G. Spignesi Jr.
Sector Healthcare
Industry Medical Devices
Full time employees 193
Full time employees 193

Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications. In addition, the company offers RMBNucleus software for the Growth Direct system; RMBNucleus Mold Alarm signals at the first sign of mold detection; RMBNucleus Central Manager portal streamlines coordination of multiple instruments; and Growth Direct LIMS connection software. Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. The company was incorporated in 2006 and is headquartered in Lowell, Massachusetts.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​